NCT04625361View on ClinicalTrials.gov

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

January 6, 2022

Study Completion Date

January 6, 2022

Conditions

Parkinson Disease

Interventions

DRUG

HEC122505MsOH

Part2：Mulltiple doses once daily, up to 8 days

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04625361 - Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter